The latest #NephTrials online discussion took place on March 10. Access the Twitter thread here. Twitter attendees joined Ron Gansevoort, Roberto Pecoits-Filho, Joel Topf, Manasi Bapat, and Swapnil Hiremath to discuss the RENAL LIFECYCLE trial. The conversation examined the composite and secondary outcomes of a randomized control trial investigating the effects of dapagliflozin on people with severe...
The next #NephTrials will be held on March 10, 2023, at 3 p.m. CET! Join Ron Gansevoort, primary investigator of the RENAL LIFECYCLE trial, in conversation with Michael Walsh, Roberto Pecoits-Filho, Joel Topf, Manasi Bapat, and Swapnil Hiremath. The panel will examine the composite and secondary outcomes of a randomized control trial investigating the effects...
The full DAPA-CKD trial results will be presented and reviewed at the ESC Congress 2020, Sunday, August 30, 17:00 – 17:30 CET. Topic Renal failure and Cardiovascular Disease Chairpersons Rory Collins (Oxford, UK); Frank Ruschitzka (Zurich, Switzerland) Presentations: DAPA-CKD – Dapagliflozin in Patients with CKD: Hiddo Heerspink (Groningen, Netherlands) DAPA- CKD – Live Prime Discussion: Diederick E Grobbee (Utrecht, Netherlands) Q&A Session The...
The ISN-ACT (Advancing Clinical Trials) team presents this monthly round up of randomized trials in nephrology. Trials are selected not just for impact, but also to showcase the diversity of research produced by the global nephrology community. Each trial is reviewed in context and has a risk of bias assessment. We hope to drive...
Jan 2023 Edition Impact Factor 2022 19.6Kidney International 5.5Kidney International Supplements 6.0Kidney International Reports Recent publications in Kidney International Reports discuss the roles of glucose, blood pressure, and cardiovascular complications in chronic kidney disease. Over the past three months, Kidney International has published several studies on the specific effects of SGLT2 inhibitors, lipotoxicity, genetics, endothelial stress responses,...
The ISN-ACT (Advancing Clinical Trials) team presents this monthly round up of randomized trials in nephrology. Trials are selected not just for impact, but also to showcase the diversity of research produced by the global nephrology community. Each trial is reviewed in context and has a risk of bias assessment. We hope to drive...
The ISN-ACT (Advancing Clinical Trials) team presents this monthly round up of randomized trials in nephrology. Trials are selected not just for impact, but also to showcase the diversity of research produced by the global nephrology community. Each trial is reviewed in context and has a risk of bias assessment. We hope to drive...
The ISN-ACT (Advancing Clinical Trials) team presents this monthly round up of randomized trials in nephrology. Trials are selected not just for impact, but also to showcase the diversity of research produced by the global nephrology community. Each trial is reviewed in context and has a risk of bias assessment. We hope to drive...
REGISTRATION ISN Webinar: Diabetes and its cardiac outcomes in people with and without kidney disease (CV outcome trials) Kidney failure and cardiovascular complications are critical complications in diabetic patients. Further, kidney disease is a significant risk for cardiovascular events independently of classical risk factors, which is called cardiorenal connection. Recent large-scale cardiovascular outcome studies such as...
Every month the ISN-ACT Team lists interesting new randomized controlled trials (RCTs) from around the world. Highlight: SGLT-2 inhibition strikes again Dapagliflozin in Patients with Chronic Kidney Disease See the latest trials here. A summary of the highlighted trial is now available in French, Mandarin, and Spanish. Support equal access to nephrology research: Become an ISN Member!
In celebration of the 60th Anniversary of the ISN, the ISN Research Working Group (RWG), under the leadership of Chair, Adeera Levin, and Deputy Chair, Masaomi Nangaku, publishes a monthly series, “Breakthrough Discoveries”. This series highlights 60 + 1 historical discoveries of significant impact to the nephrology community. So that the selection of discoveries was...
